CRL · 8-K · 20260805PR000115
Operating Expense Trends
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-08-05 · Importance 35 · Surprise 22 · In source text
Second-quarter selling, general and administrative expense increased to $228.9 million from $191.5 million, a $37.3 million or 19.5% year-over-year increase. Unallocated corporate overhead increased to $106.4 million from $70.5 million on a reported basis, while non-GAAP corporate overhead increased to $72.1 million from $60.7 million. The company recorded $20.0 million of second-quarter cost-savings and efficiency-initiative adjustments, including site-consolidation and professional-services costs, compared with $7.7 million in the prior-year quarter. Six-month SG&A was $388.3 million versus $369.3 million, while six-month cost-savings and efficiency-initiative adjustments were $1.5 million versus $12.8 million.
Key facts
- Guidance assumes acquisition-related amortization of approximately $2.30 per share for 2026. source
- Guidance includes acquisition- and divestiture-related costs of approximately $4.75 per share (current) versus ~$2.30 prior. source
- Guidance includes costs associated with restructuring and efficiency initiatives of approximately $1.20 per share (current) versus ~$0.85 prior. source
- Guidance 'Other, net' adjustment: ($0.17). source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | probable | — | Guidance assumes acquisition-related amortization of approximately $2.30 per share for 2026. |
| operating_income | negative | probable | — | Guidance includes acquisition- and divestiture-related costs of approximately $4.75 per share (current) versus ~$2.30 prior. |
| operating_income | negative | committed | — | Guidance includes costs associated with restructuring and efficiency initiatives of approximately $1.20 per share (current) versus ~$0.85… |
| net_income | negative | committed | — | Guidance 'Other, net' adjustment: ($0.17). |